Drug screening in urine increasingly carries serious legal implications, such as in school testing, workplace testing, child custody cases, and probation compliance. Positive results from preliminary screening must be confirmed, but confirming unexpected negative results is equally important—missing a maintenance drug could lead to a patient's dismissal from a clinic or job. Laboratories face challenges including chain of custody, sample stability, and long-term storage for potential legal review. As designer drugs proliferate, labs must expand detection capabilities, and even GC-MS results require established spectral match criteria for legal acceptance. Confidence in testing, highlighted by the OJ Simpson trial, will face more frequent legal challenges.
A synthetic version of salvinorin A, Mesyl Sal B, activates κ opioid receptors and shows potential as an anticocaine agent with fewer adverse effects than classic κ agonists. In rats, Mesyl Sal B had a longer duration of action than salvinorin A, reduced cocaine-seeking behavior, and increased dopamine transporter function in vitro through a κ opioid receptor- and ERK1/2-dependent mechanism. Unlike salvinorin A, Mesyl Sal B raised the maximum rate of dopamine uptake without increasing transporter cell-surface expression. The findings suggest that salvinorin-based compounds like Mesyl Sal B warrant further study as treatments for cocaine addiction, though their side-effect profile requires additional investigation.